Drugs / MMC
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT07829783 Background | Oct 2026 → Nov 2031 expected | urinary bladder cancer | Merck Sharp & Dohme LLC | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MMC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07829783 ↗ |
| Route | Intravenous | “IV infusion” NCT07829783 ↗ |